Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: A randomized, triple blind, placebo-controlled clinical trial.

Ghazal Sadat Askarpour MoezianSeyed Alireza JavadiniaSoodabeh Shahid SalesAzar FanipakdelSepideh ElyasiGholamreza Karimi

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)

Oral administration of silymarin could significantly reduce hepatotoxicity severity after 1 month of treatment in non-metastatic breast cancer patients treated with AC-T regimen.

Keyphrases

metastatic breast cancer
drug induced
clinical trial
double blind
placebo controlled
phase ii
study protocol
randomized controlled trial
drug delivery
high glucose
diabetic rats
phase iii
open label
combination therapy
oxidative stress
endothelial cells
phase ii study
replacement therapy